Do women with ovarian cancer live longer if poly (ADP-ribose) polymerase inhibitors (PARPi) are used in their treatment, and do PARPi cause unwanted effects?

1 outlet · first reported by Cochrane Evidence 14h ago

Coverage, in order

14h ago

Cochrane Evidence UK indie study
Do women with ovarian cancer live longer if poly (ADP-ribose) polymerase inhibitors (PARPi) are used in their treatment, and do PARPi cause unwanted effects?
Key messages Compared to an inactive 'dummy' medication (placebo), medications called PARPi (poly (ADP-ribose) polymerase inhibitors) given as a daily tablet for maintenance treatment (to prevent/delay cancer coming back) after chemotherapy: may increase length of life (survival) of women with…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.